Abstract: Anti-pruritic pharmaceutical formulations containing kappa agonist compounds and methods of prevention or treatment of pruritus in a mammal with the anti-pruritic formulations.

Abstract: This invention provides a method for preventing or treating type I diabetes in a mammal comprising administering the mammal an effective amount of at least one compound of the formula I: ##STR1## The invention also provides pharmaceutical preparations useful for the prevention and/or treatment of type I diabetes comprising an effective amount of at least one compound of the formula previously set forth and a pharmaceutically acceptable carrier.

Abstract: The invention relates to the administration of guanylate cyclase inhibitors, such as methylene blue, for the treatment of septic shock, cardiogenic shock, hypovolemic shock, obstructive shock, neuropathic shock and hypotension caused by excessive doses of nitrovasodilators. The invention also relates to the use of other redox dyes, such as toluidine blue, neutral red, tetrazolium salts, chloranil and dichlorophenolindophenol for the treatment of shock.

Abstract: The present invention relates to a topical skin care formulation comprised of micronized calcium citrate and salicylic acid. This composition provides a method for treating acne as well as providing for a variety of skin beautification products which are especially applicable to sensitive skin.

Abstract: Inflammatory bowel disease is treated, and patients are protected from a relapse into active disease, by the administration of a compound chosen from a series of 3-phenyl-5-carboxypyrazoles and isothiazoles.

Abstract: A pharmaceutical product to be used as an adjuvant treatment of seborrheic dermatitis even in HIV positive subjects is disclosed. The pharmaceutical product makes use of methionine, vitamin E and selenium as active principles which directly or indirectly provide a protective response to the damage caused by lipoperoxidation. The pharmaceutical product, in combination with a diet rich in PUFA-PL (polyunsaturated fatty acids of phospholipids), causes skin homeostasis to be restored and the symptoms of skin dermatitis to regress.

Abstract: A method for suppressing an immune response in a mammal by treating the mammal with an effective amount of spiperone derivative that is without significant neuroleptic effect due to decreased binding to serotonin and/or dopamine receptors as compared with unmodified or uncomplexed spiperone, or due to topical application which maximizes local immunosuppression while limiting systemic absorption and neuroleptic effects. The spiperone derivatives are capable of inhibiting classic contact hypersensitivity reactions.

Abstract: The use of alkylphosphoric acid compounds of Formula IR--Y--PO.sub.2.sup..crclbar. --X--R.sub.1 Iwhere in Formula IR represents a saturated or unsaturated hydrocarbon radical with 12 to 24 carbon atoms or where R represents the group--CH.sub.2 --CHR.sub.3 --CH.sub.2 --Z--R.sub.4 and R.sub.3 is a C.sub.1 -C.sub.6 -alkoxy group or a C.sub.1 -C.sub.6 -alkoxymethyl group,Z represents oxygen or sulphur and R.sub.4 represents a C.sub.1 -C.sub.24 -alkyl radical,X is an oxygen atom, NH or NR.sub.2 and Y is an oxygen atom or NH, R.sub.1 is a C.sub.1 -C.sub.8 -alkyl group, or where R.sub.1 represents a C.sub.2 -C.sub.8 -alkyl group which is unsaturated and/or substituted by halogen, amino, C.sub.1 -C.sub.6 -alkylamino, di-C.sub.1 -C.sub.6 -alkylamino, tri-C.sub.1 -C.sub.6 -alkylamino, hydroxy, carboxy, C.sub.3 -C.sub.8 -cycloalkyl or phenyl for the preparation of a pharmaceutical composition for combating psoriasis disorders.

Abstract: The present invention provides a new medical use for the phenethanolamine compound 4-hydroxy-.alpha..sup.1 -[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol and physiologically acceptable salts and solvates thereof in the treatment of inflammation, allergy and allergic reaction.

Abstract: Compositions for topical treatment of lesions of human or animal skin which comprise dimethyl ether to freeze the tissue and an acid capable of dissolving the intercellular matrix of the lesion. The dimethyl ether and acid are present in the composition in amounts effective to remove the lesion in a single treatment by a combination of cryogenic and keratolytic action. Methods are provided for the topical treatment of lesions of the skin of human or animal subjects comprising direct spray or intermediate swab application of the present compositions to the lesions.

Abstract: This invention encompasses pharmaceutical compositions and a dietary supplement for treating or preventing alcoholic cirrhosis of the liver which comprises administering about 1 to 3 grams per day of dilinoleoylphosphatidylcholine (DLPC).

Abstract: A method is disclosed for normalizing blood glucose and insulin levels as measured by an oral glucose tolerance test in an individual exhibiting normal fasting blood glucose and insulin levels and exhibiting in an oral glucose tolerance test elevated glucose levels and at least one insulin level abnormality selected from the group consisting of a delayed insulin peak, an exaggerated insulin peak and a secondary elevated insulin peak. The method comprises administering diazoxide to the individual before ingestion of a food source in an amount effective to normalize the blood glucose and insulin levels. Diazoxide is administered in an amount from about 0.4 to about 0.8 mg/kg body weight before each meal.

Abstract: The present invention provides a new medical use for the dichloroaniline 4-amino-3,5-dichloro-.alpha.-[[[6-[2-(2-pyridinyl)ethoxy]hexyl]amino]methy l]benzenemethanol and its enantiomers, and physiologically acceptable salts and solvates thereof in the treatment of inflammation, allergy and allergic reaction.

Abstract: A pharmaceutical composition for the treatment of autoimmune diseases comprising an effective amount of a compound of formulaA--CH.sub.2 --O--CRR'--COOR"' (I)whereA is the nucleus of 1-benzyl-indazol-3-yl,R and R', the same or different from each other, are H or an alkyl having from 1 to 5 carbon atoms,R"' is H or an alkyl having from 1 to 4 carbon atoms,or, when R"' is H, of a salt thereof with organic or inorganic pharmaceutically acceptable bases.

Abstract: Premature ejaculation by a male human patient is treated by administration of paroxetine.

Abstract: The present invention relates to orthostatic lavage solutions or colon evacuants for cleansing the gastrointestinal tract, or for treatment of bowel diseases and/or disorders, containing an effective amount of ascorbic acid or a salt thereof.

Abstract: The use of 1,2-dipalmitoyl-L-.alpha.-phosphatidyl-N,N-dimethylethanolamine for the manufacturing of dermatological and cosmetic compositions for antiageing and cutaneous microcirculation treatment.

Abstract: Method of treating addiction in a subject, such as a human being, by administering, to the subject, a succession of therapeutic agents. Each of these agents competes with the addictive agent for receptor binding sites, and each is administered in an amount sufficient to remove addictive agent from the subject. At least one of these therapeutic agents controls withdrawal symptoms. The method is continued until at least one of the indicated therapeutic agents fails to evoke withdrawal symptoms in the subject.

Abstract: Compounds of the formulas ##STR1## wherein R.sup.1 is H and R.sup.2 is alkyl (3-8C) or wherein R.sup.1 and R.sup.2 taken together are --(CH.sub.2).sub.n -- wherein n=3-5;R.sup.3 is H or alkyl (1-4C);R.sup.4 is a substituted or unsubstituted fused or conjugated bicycloaryl methylene;X is OR.sup.5 or NHR.sup.5, wherein R.sup.5 is H or substituted or unsubstituted alkyl (1-12C), aryl (6-12C), aryl alkyl (6-16C); orX is an amino acid residue or amide thereof; orX is the residue of a cyclic amine or heterocyclic amineare useful for treating or preventing ulceration of tissue, especially cornea.

Abstract: A method of relieving erectile impotence in a human male. The method comprises administering to the male an erectile impotence relieving amount of a compound selected from the group consisting of U.K. 52,046, Amlodipine, Doxazosin and the pharmaceutically acceptable acid addition salts thereof.